All rights reserved. Clinical trial information: NCT04221542.doi:10.1200/JCO.2021.39.6_suppl.TPS183William Kevin KellyDavid William PookLeonard Joseph ApplemanDavid Michael WaterhouseTanya B. DorffJournal of Clinical Oncology
AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment.Significance:Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and ...